Literature DB >> 21761368

Androgen action in prostate cancer.

Sujit Basu1, Donald J Tindall.   

Abstract

Prostate cancer represents a major health problem in men worldwide. Androgens are required for the growth and maintenance of the prostate. Androgens act by binding to the androgen receptor (AR), a nuclear receptor transcription factor present in the prostate tissues. Most prostate tumors also retain their androgen dependence; therefore, androgen ablation is usually the preferred initial therapeutic approach for the treatment of advanced prostate cancer patients. This review summarizes the current information regarding the role of androgens in prostate cancer. © Springer Science+Business Media, LLC 2010

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21761368     DOI： 10.1007/s12672-010-0044-4

Source DB:  PubMed          Journal:  Horm Cancer        ISSN： 1868-8497            Impact factor:   3.869


  57 in total

Review 1.  Transcriptional coactivator complexes.

Authors:  A M Näär; B D Lemon; R Tjian
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 2.  Androgen receptors and their biology.

Authors:  D J Lamb; N L Weigel; M Marcelli
Journal:  Vitam Horm       Date:  2001       Impact factor: 3.421

3.  Androgens and prostate cancer: are the descriptors valid?

Authors:  Pradip Roy-Burman; Donald J Tindall; Diane M Robins; Norman M Greenberg; Mary J C Hendrix; Suresh Mohla; Robert H Getzenberg; John T Isaacs; Kenneth J Pienta
Journal:  Cancer Biol Ther       Date:  2005-01       Impact factor: 4.742

Review 4.  Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.

Authors:  W D Figg; J A Feuer; K S Bauer
Journal:  Cancer Pract       Date:  1997 Jul-Aug

5.  Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.

Authors:  A S Wright; L N Thomas; R C Douglas; C B Lazier; R S Rittmaster
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

6.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Authors:  Mary-Ellen Taplin; Barur Rajeshkumar; Susan Halabi; Cary P Werner; Bruce A Woda; Joel Picus; Walter Stadler; Daniel F Hayes; Philip W Kantoff; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 8.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

9.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Authors:  M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

10.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.

Authors:  Mara P Steinkamp; Orla A O'Mahony; Michele Brogley; Haniya Rehman; Elizabeth W Lapensee; Saravana Dhanasekaran; Matthias D Hofer; Rainer Kuefer; Arul Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Diane M Robins
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701
View more
  17 in total

1.  Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells.

Authors:  Mehmet Korkmaz; Cigir Biray Avcı; Cumhur Gunduz; Duygu Aygunes; Burcu Erbaykent-Tepedelen
Journal:  Tumour Biol       Date:  2014-02

2.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

Review 3.  Mini-review: androgen receptor phosphorylation in prostate cancer.

Authors:  Garrett Daniels; Zhiheng Pei; Susan K Logan; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

4.  Mice lacking β-carotene-15,15'-dioxygenase exhibit reduced serum testosterone, prostatic androgen receptor signaling, and prostatic cellular proliferation.

Authors:  Joshua W Smith; Nikki A Ford; Jennifer M Thomas-Ahner; Nancy E Moran; Eric C Bolton; Matthew A Wallig; Steven K Clinton; John W Erdman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

5.  An androgen-independent mechanism underlying the androgenic effects of 3-methylcholanthrene, a potent aryl hydrocarbon receptor agonist.

Authors:  Noriko Sanada; Yuka Gotoh-Kinoshita; Naoya Yamashita; Ryoichi Kizu
Journal:  Toxicol Res (Camb)       Date:  2020-05-14       Impact factor: 3.524

6.  Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Authors:  Maria E Suarez-Almazor; Prashanth Peddi; Ruili Luo; Hoang T Nguyen; Linda S Elting
Journal:  Support Care Cancer       Date:  2013-10-22       Impact factor: 3.603

7.  Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells.

Authors:  Anbalagan Jaganathan; Pratima Chaurasia; Guang-Qian Xiao; Marc Philizaire; Xiang Lv; Shen Yao; Kerry L Burnstein; De-Pei Liu; Alice C Levine; Shiraz Mujtaba
Journal:  Mol Endocrinol       Date:  2014-04-04

8.  Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Sanna Kaikkonen; Ville Paakinaho; Päivi Sutinen; Anna-Liisa Levonen; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2012-11-28

Review 9.  Anticancer activity of green tea polyphenols in prostate gland.

Authors:  Pierpaola Davalli; Federica Rizzi; Andrea Caporali; Davide Pellacani; Serena Davoli; Saverio Bettuzzi; Maurizio Brausi; Domenico D'Arca
Journal:  Oxid Med Cell Longev       Date:  2012-05-15       Impact factor: 6.543

10.  Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.

Authors:  Hui-Wen Chiu; Yi-An Chen; Sheng-Yow Ho; Ying-Jan Wang
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.